AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00609986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140.
Study NCT00609986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH Insulin or glargine insulin and aspartame insulin
Description: The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL
Study NCT01856244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treadmill walking
Study NCT01856244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill walking
Study NCT01856244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Study NCT01856244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Study NCT03625050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna + Usual care(Celecoxib and esomeprazole)
Description: Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen.
Study NCT03625050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care(Celecoxib and esomeprazole)
Description: Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
Study NCT02921074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Study NCT02921074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study NCT04168866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative management
Description: Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
Study NCT04168866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drainage or antibiotics
Description: If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
Study NCT02988180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: basic services
Description: The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
Study NCT02988180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the play-based developmental stimulation
Description: Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
Study NCT01641328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogntive Activation Training
Description: Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
Study NCT01641328 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control / Home-based training
Description: Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
Study NCT01070732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
Study NCT02899689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan
Description: Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
Study NCT02899689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
Study NCT04329481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mycodigest supplement
Description: Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder
Study NCT04329481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mycodigest supplement
Description: Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder
Study NCT02806128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallidinogenase for Injection
Description: Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
Study NCT00930839 — intervention group
Intervention type: DRUG
Intervention: Niacin and aspirin
Description: 1000 mg Niacin, 325 mg aspirin
Study NCT01415011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib (BIBW 2992)
Description: All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
Study NCT04100681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active FlowOx™
Description: Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
Study NCT04100681 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham FlowOx™ (Placebo)
Description: Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
Study NCT00025220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study NCT00025220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00870220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Description: GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
Study NCT03314077 — intervention group
Intervention type: OTHER
Intervention: GOLD 2017
Description: Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
Study NCT03885427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: evaluate sedative, and analgesic effects of oral or nebulized ketamine
Study NCT03885427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: evaluate sedative, and analgesic effects of oral or nebulized ketamine
Study NCT04326712 — intervention group
Intervention type: OTHER
Intervention: conventional manufactured socket
Description: Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
Study NCT04326712 — intervention group
Intervention type: OTHER
Intervention: 3D manufactured socket
Description: Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
Study NCT03778411 — intervention group
Intervention type: DEVICE
Intervention: VCTE with splenic stiffness measurement
Description: Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
Study NCT01878526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alginic acid
Description: Algycon 1 tab chew tid after meal
Study NCT01878526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (for domperidone)
Description: placebo (for domperidone) 1 tab oral tid before meal
Study NCT01878526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: domperidone (10 mg) 1 tab oral tid before meal
Study NCT01878526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (of alginic acid)
Description: placebo (for alginic acid) 1 tab chew tid after meal
Study NCT05584982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtbFinder
Description: In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
Study NCT02524470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - NEHB Configuration
Description: VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
Study NCT02524470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSP System - PAL Configuration
Description: VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
Study NCT01969994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled dietary background
Description: Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
Study NCT01969994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (-)-[2-14C]epicatechin intake
Description: Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.
Study NCT03996876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RePS (Resolving Psychological Stress) - Threat ABM Training
Description: This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
Study NCT03996876 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RePS (Resolving Psychological Stress) - Neutral Attention Training
Description: This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
Study NCT01766128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: The first arm will be treated by zonisamide
Study NCT01766128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The second arm will receive placebo
Study NCT03321227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack skipping
Description: No snack provided
Study NCT03321227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole eggs
Description: 2 whole large eggs scrambled, provided as a snack
Study NCT03321227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg whites
Description: 2 egg whites scrambled, provided as a snack
Study NCT03321227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg yolks
Description: 2 egg yolks scrambled, provided as a snack
Study NCT03321227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt
Description: A serving of full fat yogurt that is isocaloric to the 2 whole eggs
Study NCT00867321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00867321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00474110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine & hydromorphone
Description: See Detailed Description
Study NCT03565575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive tablet-based quiz
Description: Intervention participants play an interactive tablet based quiz including the following information components:~1. Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~2. Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures.
Study NCT01798368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE system 2.0
Study NCT03697720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Participants will take naproxen 500mg BID before and for the first 3 days of their period.
Study NCT02871973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
Study NCT02871973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
Study NCT01688284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopy
Description: Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
Study NCT04516317 — intervention group
Intervention type: OTHER
Intervention: None (Observational study Group intravenous artesunate)
Description: Retrospective descriptive study of Group intravenous artesunate
Study NCT04516317 — intervention group
Intervention type: OTHER
Intervention: None (Observational study Group intravenous quinine)
Description: Retrospective descriptive study of Group intravenous quinine
Study NCT00774280 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: BuCy vs BuFlu
Description: Arm 1:BuCy Arm 2:BuFlu
Study NCT02536768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimum package of interventions to improve ART adherence
Description: Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
Study NCT02349399 — intervention group
Intervention type: DRUG
Intervention: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics
Description: Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
Study NCT00382720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin
Description: Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1
Study NCT00382720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin + 5-FU
Description: Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1.
Study NCT00382720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Oxaliplatin + Capecitabine
Description: Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously.
Study NCT01508104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: dose escalation 400mg- 1000mg per day
Study NCT01508104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: dose escalation 2.5 to 5 mg per day
Study NCT03377842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
Study NCT03377842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib and FOLFOX regimen
Description: Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
Study NCT00829049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream 0.1%
Description: 1 pea-size amount, QD x 16 weeks
Study NCT00829049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: 1 pea-size amount, QD x 16 weeks
Study NCT01819649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Study NCT01819649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S
Study NCT00880659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soap
Description: Promotion of handwashing with soap
Study NCT00182832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)
Description: Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
Study NCT00182832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care for hospitalized older patients with cognitive impairment